Burrows Scott L (CIK 1853327) reported 29 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-03). Recent activity: Buy SYRE (7,500 shares), Sell SYRE (900 shares), Sell SYRE (4,384 shares), Sell SYRE (2,016 shares), Sell SYRE (200 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Buy | 7,500 | $108,750 |
| 2026-09-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 900 | $77,625 |
| 2026-09-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 4,384 | $381,890 |
| 2026-09-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 2,016 | $177,468 |
| 2026-09-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 200 | $17,808 |
| 2026-09-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 18,232 | $1.6M |
| 2026-08-05 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Buy | 7,500 | $108,750 |
| 2026-08-05 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 5,100 | $485,571 |
| 2026-08-05 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 2,300 | $221,490 |
| 2026-08-05 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 100 | $9,710 |
| 2026-07-02 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 1,725 | $152,438 |
| 2026-07-02 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 5,775 | $505,601 |
| 2026-07-02 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Buy | 7,500 | $108,750 |
| 2026-06-26 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Buy | 15,000 | $217,500 |
| 2026-06-26 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 5,000 | $435,600 |
| 2026-06-26 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 10,000 | $871,400 |
| 2026-06-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Buy | 7,500 | $108,750 |
| 2026-06-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 1,801 | $125,620 |
| 2026-06-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 2,599 | $183,931 |
| 2026-06-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 3,100 | $223,386 |
| 2026-05-01 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Buy | 12,500 | $181,250 |
| 2026-05-01 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 12,500 | $892,125 |
| 2026-04-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Buy | 7,500 | $108,750 |
| 2026-04-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 6,200 | $305,102 |
| 2026-04-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 1,300 | $64,974 |
来源：SEC Form 4 申报文件 · 截至 2026-09-03